Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Δ	I	I	IC	ΔТ	$\cap$	2	FN	IFR	GY	I	IN	11	Т	$\mathbf{F}$	n
$\overline{}$	ч	₁ـــ	ıυ.	$\Lambda$ 1	. OI	`	LIN			_	41 I V	11			ப

ABN

79 140 575 604

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- <sup>†</sup>Class of \*securities issued or to be issued
- 1. Ordinary Shares and
  Unlisted Share Options (attaching)
  (previously included in Appendix 3B
  released on 16 Oct 2019 now approved
  by Shareholders and allotted)
- 2. Ordinary Shares
- 3. Ordinary Shares
- 4. Ordinary Shares
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 1. **Share Placement Tranche 2** 136,000,000 ordinary shares and 130,000,000 unlisted options to acquire ordinary shares
- 2. **Share Purchase Plan allotment** 120,000,000 ordinary shares
- 3. **Director Fee Plan Issue** 5,333,333 ordinary shares
- 4. **Introduction Share Issue** 3,000,000 ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

- Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
- 1. Ordinary fully paid shares (New Shares) being Tranche 2 of the placement announced to the ASX on 16 October 2019. Shareholder approval was obtained at the 2019 AGM and the allotment of the Tranche 2 placement along with the issue of all Unlisted Share Options (set out below) has now been completed
  - 1 attaching Unlisted Share Option was issued for every 2 New Shares (both Tranche 1 and Tranche 2) under the placement. These are subject to an exercise price of \$0.005 and expiry date of 12 months from the date of issue being 4 December 2020.
- 2. Ordinary fully paid shares
- 3. Ordinary fully paid shares
- 4. Ordinary fully paid shares

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

Ordinary fully paid shares in issues 1,2,3 and 4– Yes

Attaching Unlisted Share Options- No

The Attaching Unlisted Share Options have an exercise period which expires twelve months from issue and can be converted into ordinary shares at \$0.005. The Attaching Options do not have any rights to vote or to participate in dividends.

- 1. \$0.0025 per share
- 2. \$0.0025 per share
- 3. \$0.003 per share
- 4. \$0.003 per share

<sup>+</sup> See chapter 19 for defined terms.

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

#### The purpose for issues 1 and 2 above:

- completing the Big Lake Uranium transaction and commencing the planned work program including delineation of key target paleochannels and air core drilling of the defined channels;
- 2. to retain the Company's existing uranium and energy mineral projects in good standing;
- 3. investigating other opportunities; and
- 4. general working capital.

#### The purpose for issue 3:

Issue to Directors or their nominees under the terms of Resolution 4 (Accrued Director Fee Shares) approved by Shareholders at the 2019 AGM. The allotment relates to the quarter ended 30 September 2019. A total of \$16,000 in director fees was applied for in Fee Plan Shares.

#### The purpose for issue 4:

Issue of Introduction Shares to Taycol Nominees Pty Ltd in relation to the Big Lake Uranium Farm-in Agreement which was approved by Shareholders at the 2019 AGM.

6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6с	Number of *securities issued without security holder approval under rule 7.1	N/A

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	N/A
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1 – 191,042,476
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	<ol> <li>4 December 2019</li> <li>4 December 2019</li> <li>4 December 2019</li> <li>4 December 2019</li> </ol>

<sup>+</sup> See chapter 19 for defined terms.

8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
1,412,023,894	Ordinary Shares
310,393,619	Options- exercisable
	at \$0.021 per option
	before 27 December
	2019 - subject to
	being able to meet
	ASX Listing Rule
	requirements.

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
7,500,000	Options exercisable at \$0.00 if vesting conditions are met before 28 February 2020
2,913,158	Options exercisable at \$0.00 if vesting conditions are met before 7 March 2020
4,250,000	Options exercisable at \$0.00 if vesting conditions are met before 2 May 2021
7,500,000	Options exercisable at \$0.00 if vesting conditions are met before 19 July 2022
130,000,000	Options exercisable at \$0.005 for twelve months before 4 December 2020)

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

There is no change in the dividend policy

#### Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	*Record date to determine	N/A
	entitlements	

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A
You nee	3 - Quotation of securities and only complete this section if you are ap	
34	Type of *securities (tick one)	
(a)	*Securities described in Part	. 1
(b)	•	nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible
	employee incentive share securities who	en restriction ends, securities issued on expiry or conversion of convertib

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

Tick to locum	te you are providing the information or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	Not Applicable	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	Not Applicable	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Not Applicable	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
		NY . A 11 1.1	
41	Reason for request for quotation now	Not Applicable	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Not Applicable	Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Company Secretary

Print name: Mike Meintjes

== == == == ==

Date: 5 December 2019

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exc	ceeding 15% of capital
Step 1: Calculate "A", the base figures capacity is calculated	ure from which the placement
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	988,207,452
Add the following:	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	135,291,667
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	283,515,116
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	-
"A"	1,407,014,235

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	211,052,135
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	20,009,659
• Under an exception in rule 7.2	
• Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	20,009,659
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	211,052,135
Note: number must be same as shown in Step 2	
Subtract "C"	20,009,659
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	191,042,476
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A"	N/A
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	N/A
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
<ul> <li>Insert number of †equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	N/A
"E"	N/A

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	N/A
Note: number must be same as shown in Step 2	
Subtract "E"	N/A
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	N/A
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 16 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.